Skip to Content

Join the 'Rituxan' group to help and get support from people like you.

Rituxan News

Rituximab (Rituxan) May Delay MS Disability for Some

Posted 11 days ago by Drugs.com

WEDNESDAY, Jan. 9, 2019 – An immune system drug may help prevent or slow complications in a type of multiple sclerosis known as secondary progressive MS, a new study finds. The medication is called rituximab (Rituxan). It's used to treat a number of conditions, including certain blood cell cancers and the autoimmune condition rheumatoid arthritis. The new Swiss study found that MS patients ...

Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug

Posted 29 Nov 2018 by Drugs.com

WEDNESDAY, Nov. 28, 2018 – Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said Wednesday. A biosimilar is a biological product that is approved based on data showing it is "highly similar" to a drug already approved by the FDA, with no "clinically meaningful differences in terms of ...

FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan for Non-Hodgkin’s Lymphoma

Posted 28 Nov 2018 by Drugs.com

November 28, 2018 – The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy. Truxima is the first biosimiliar to be approved in the U.S. for the treatment of non-Hodgkin’s l ...

FDA Approves Imbruvica (ibrutinib) Plus Rituximab for Patients with Waldenström’s Macroglobulinemia

Posted 1 Sep 2018 by Drugs.com

HORSHAM, Pa., August 27, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia (WM), a rare blood cancer.[1] The approval expands the label for Imbruvica in WM beyond its current approved use as a monotherapy to ...

Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia

Posted 12 Jun 2018 by Drugs.com

South San Francisco, CA – June 8, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have ...

FDA Approves Genentech’s Rituxan (rituximab) for Pemphigus Vulgaris

Posted 12 Jun 2018 by Drugs.com

South San Francisco, CA – June 7, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterized by progressive painful blistering of the ...

Adding Rituximab to Standard Care May Prolong Lymphoma Survival

Posted 28 Sep 2017 by Drugs.com

WEDNESDAY, Sept. 27, 2017 – Long-term treatment with the drug rituximab (Rituxan) may extend the lives of some patients with a rare form of blood cancer, a new clinical trial finds. The disease, known as mantle-cell lymphoma, is generally incurable. But various treatments can prolong people's lives. Some patients, for instance, are able to undergo chemotherapy to wipe out the cancer cells, ...

Novel Procedure Improves Kidney Transplant Success

Posted 3 Aug 2017 by Drugs.com

WEDNESDAY, Aug. 2, 2017 – A new treatment might open the door for more patients with advanced kidney disease to get a transplant, a preliminary study suggests. Of the 100,000-plus Americans waiting for a donor kidney, about one-third are "sensitized," said Dr. Robert Montgomery, director of the Transplant Institute at NYU Langone in New York City. Those patients face a tough situation: They ...

FDA Approves Rituxan Hycela (rituximab and hyaluronidase human) for Subcutaneous Injection in Certain Blood Cancers

Posted 26 Jun 2017 by Drugs.com

South San Francisco, CA – June 22, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Early Treatment Equals Better Results for Rheumatoid Arthritis

Posted 25 Apr 2017 by Drugs.com

TUESDAY, April 25, 2017 – Treating rheumatoid arthritis early may make for better outcomes, a new study suggests. Patients who were treated within six months of developing the first signs of the autoimmune disease did better in the long run and were less likely to suffer early death, British researchers found. The findings stem from an analysis of more than 600 patients who were initially ...

Could a Germ Link Gum Disease, Rheumatoid Arthritis?

Posted 15 Dec 2016 by Drugs.com

THURSDAY, Dec. 15, 2016 – A specific germ may help explain the long-noticed connection between gum disease and rheumatoid arthritis, a new study suggests. The discovery might also point to the potential origins of the painful joint illness. "If we're right, this will totally change the view of rheumatoid arthritis and treatment of patients," said study co-author Dr. Felipe Andrade. But, Andrade, ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

Study Suggests Causes for Lupus' Impact on Immune System

Posted 8 Mar 2016 by Drugs.com

TUESDAY, March 8, 2016 – Scientists have found new clues that help explain what's going wrong in the immune systems of people with lupus – insight they hope will lead to new therapies, or help guide current treatment choices. Lupus has several forms, but the most common is systemic lupus erythematosus (SLE). In SLE, the immune system mistakenly produces antibodies against the body's own tissue. ...

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Rheumatoid Arthritis

Rituxan Patient Information at Drugs.com